Viewing Study NCT06952504


Ignite Creation Date: 2025-12-24 @ 9:09 PM
Ignite Modification Date: 2025-12-27 @ 8:42 PM
Study NCT ID: NCT06952504
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2025-04-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module